Eli Lilly (LLY) Stock Surges Past $1,200 as GLP-1 Dominance Continues in 2026

Key Highlights

Table of Contents

Eli Lilly shares started Friday trading at $1,208.37, marking a 14.4% gain for the year and outpacing the S&P 500
The company’s GLP-1 medications Mounjaro and Zepbound generated roughly 65% of first-quarter 2026 revenue
New oral obesity treatment Foundayo hit the market, with GLP-1 drugs projected to surpass 65% of Q2 sales
First-quarter earnings per share reached $8.55, crushing the $6.97 forecast, while revenue of $19.80 billion jumped 55.5% versus last year
The pharmaceutical giant deployed over $20 billion across multiple acquisitions and strategic partnerships throughout 2026 to expand beyond GLP-1 therapies

Eli Lilly (LLY) shares began Friday’s session at $1,208.37, hovering close to the 52-week peak of $1,238.00. Year-to-date performance shows a 14.4% advance, surpassing both the pharmaceutical sector’s 11.6% rise and the broader S&P 500 index.

Eli Lilly and Company, LLY

The pharmaceutical company delivered first-quarter 2026 earnings of $8.55 per share, significantly exceeding Wall Street’s $6.97 projection. Total revenue reached $19.80 billion, beating the $17.82 billion forecast and representing a 55.5% year-over-year surge.

The company’s twin GLP-1 blockbusters, Mounjaro and Zepbound, powered the majority of this expansion. These two medications alone contributed approximately 65% of all first-quarter sales. Following the U.S. rollout of Foundayo — the company’s oral formulation targeting obesity — analysts anticipate GLP-1 drugs will account for more than 65% of second-quarter revenue.

Foundayo’s arrival renews the competitive battle with Novo Nordisk (NVO), which introduced an oral variant of Wegovy in January 2026, securing an early market advantage.

Expanding the Portfolio Beyond Weight Loss Drugs

The Indianapolis-based drugmaker has been aggressively developing treatments outside the GLP-1 category to minimize dependence on its obesity and diabetes franchise.

Its diversified pipeline includes Omvoh for inflammatory bowel disease treatment, Jaypirca addressing specific blood cancer types, Ebglyss approved for atopic dermatitis patients, Kisunla designed for early-stage Alzheimer’s disease, and Inluriyo recently introduced for metastatic breast cancer.

Jaypirca has emerged as a standout performer. Regulatory authorities expanded its approved uses in late 2025 for patients experiencing relapsed or refractory CLL/SLL. The European Medicines Agency’s scientific committee has since backed broader approval across all CLL treatment stages, with final European Commission authorization expected soon.

The company awaits a comparable FDA label expansion ruling for Jaypirca before year-end. Approval would significantly widen the eligible patient base domestically.

Regarding mergers and acquisitions, Lilly allocated upward of $20 billion during 2026 across deals spanning cancer treatments, brain health, heart disease therapies, gene-editing platforms, and vaccine development. This represents a substantial commitment to long-range portfolio diversification.

Stock Valuation and Wall Street Perspective

At present trading levels, LLY carries a forward price-to-earnings ratio of 30.67 — elevated compared to the pharmaceutical industry’s 18.76 average but trailing its own five-year historical mean of 34.56. The company’s market capitalization stands at $1.14 trillion.

Full-year 2026 earnings per share projections have climbed during the past 60 days, rising from $33.86 to $35.67. Looking ahead to 2027, forecasts increased from $42.56 to $44.61.

Institutional investors control 82.53% of outstanding shares. World Investment Advisors expanded its position by 12.1% during the first quarter of 2026, purchasing 2,936 additional shares to reach a total holding of 27,134.

Wall Street sentiment leans decidedly bullish. Goldman Sachs maintains a buy recommendation with a $1,283 price objective. Jefferies recently boosted its target to $1,350, also rating the stock a buy. Morgan Stanley reaffirmed its overweight stance in June.

Among 30 analysts monitored by MarketBeat, 23 recommend purchasing shares, with the average price target settling at $1,235.07.

The sole contrarian voice: HSBC downgraded the stock to reduce in March, establishing an $850 price target.

Management’s fiscal 2026 guidance projects EPS between $35.50 and $37.00, while the sell-side consensus currently estimates $35.74.